NIH-supported trials to test synthetic antibody treatments
Researchers have launched two clinical trials to test whether monoclonal (laboratory-made) antibodies can safely prevent SARS-CoV-2 infection or symptoms in healthy adults, the National Institutes of Health announced yesterday.
One trial will evaluate a Regeneron Pharmaceuticals investigational treatment in about 2,000 asymptomatic adults who are household contacts of people infected with SARS-CoV-2.
The other will assess an Eli Lilly and Company investigational treatment in up to 2,400 people who reside or work in skilled nursing or assisted living facilities.
Related News Articles
Headline
Centers for Medicare & Medicaid Services Administrator Mehmet Oz, M.D., and CMS Deputy Administrator and Director of Medicaid and CHIP Dan Brillman sat…
Headline
Flu and COVID-19 vaccination rates among all health care workers for the 2024-25 respiratory virus season was 76.3% and 40.2%, respectively, according to a…
Headline
A study published March 18 by Science Advances estimated that more than 155,000 U.S. COVID-19 deaths were uncounted during the COVID-19 pandemic. Researchers…
Headline
The Centers for Disease Control and Prevention Feb. 19 released a report on the low use of COVID-19 antiviral drugs among individuals age 65 and older, a…
Headline
The Food and Drug Administration today released two guidance documents; one related to low-risk wellness products (including certain wearable devices) and the…
Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…